Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has shared an announcement.
Circio Holding ASA has announced the registration of a share capital increase following the conversion of convertible bonds by Atlas Special Opportunities, LLC. This development reflects the company’s ongoing financial maneuvers to support its innovative biotechnology endeavors, particularly in RNA technology and cancer vaccine development, potentially strengthening its market position and offering growth opportunities for stakeholders.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in RNA technology for nucleic acid medicine. They have developed a circular RNA vector expression platform, known as circVec, which enhances protein expression significantly compared to traditional mRNA systems. Circio is also working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,312,088
Current Market Cap: NOK70.11M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.